Daveen Chopra, Corporate Vice President, Transcatheter Mitral and Tricuspid Therapies, Surgical, and Implantable Heart Failure Management, on August 26, 2026, sold 31,800 shares in Edwards Lifesciences (EW) for $2,894,440. Following the Form 4 filing with the SEC, Chopra has control over a total of 44,324 common shares of the company, with 44,324 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1099800/000122520826007335/xslF345X05/doc4.xml
Peter J Kelly, Director, Chief Executive Officer, on August 24, 2026, executed a purchase for 14,830 shares in Openlane (OPLN) for $499,999. Following the Form 4 filing with the SEC, Kelly has control over a total of 14,830 common shares of the company, with 14,830 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1395942/000153201026000003/xslF345X05/wk-form4_1787781133.xml
Therese Tucker, Director, on August 24, 2026, sold 70,000 shares in Blackline (BL) for $2,236,990. Following the Form 4 filing with the SEC, Tucker has control over a total of 4,507,475 common shares of the company, with 381,557 shares held directly and 4,125,918 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1666134/000166613426000100/xslF345X05/form4.xml
Jeffrey David Puckett, Chief Operating Officer, on August 24, 2026, sold 8,500 shares in Tyler Technologies (TYL) for $3,029,698. Following the Form 4 filing with the SEC, Puckett has control over a total of 7,784 common shares of the company, with 7,784 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/860731/000213003526000002/xslF345X05/primary_doc.xml